research use only

3-Amino-9-ethylcarbazole

Name: 3-Amino-9-ethylcarbazole
Brand: Selleck Chemicals
SKU: E2703
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E2703

3-Amino-9-ethylcarbazole (AEC) is a chemical compound commonly used as a chromogenic substrate in immunohistochemistry, specifically for visualizing sections stained with HRP-conjugated secondary antibodies.

Chemical Structure

Molecular Weight: 210.27

Jump to

Quality Control

Batch: E270301 DMSO]42 mg/mL]false]Ethanol]21 mg/mL]false]Water]Insoluble]false Purity: 98.70%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

98.70

Related Targets	PROTAC Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture ADC Linker Molecular Glues Antibiotics for Plant Cell Culture PROTAC Linker
Other Others Products	BAY 2927088（Sevabertinib） BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole 4-Methylumbelliferone (4-MU) Dioscin

Solubility

In vitro
Batch:

DMSO : 42 mg/mL (199.74 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 21 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	210.27	Formula	C₁₄H₁₄N₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	132-32-1	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	AEC			Smiles	CC[N]1C2=CC=CC=C2C3=CC(=CC=C13)N

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/25242720/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06388889	Enrolling by invitation	Eosinophilic Asthma	Areteia Therapeutics	May 8 2024	Phase 3
NCT05813288	Recruiting	Eosinophilic Asthma\|Asthma; Eosinophilic\|Asthma	Areteia Therapeutics	March 27 2023	Phase 3
NCT05748600	Recruiting	Eosinophilic Asthma\|Asthma; Eosinophilic\|Asthma Attack	Areteia Therapeutics	January 30 2023	Phase 3
NCT05763121	Recruiting	Eosinophilic Asthma\|Asthma; Eosinophilic\|Asthma	Areteia Therapeutics	January 30 2023	Phase 3
NCT04128371	Terminated	Eosinophilia\|Angioedema	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	January 14 2021	Phase 2
NCT04191304	Recruiting	Hypereosinophilic Syndrome	AstraZeneca	July 20 2020	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):